Indolent TCL facts Flashcards
MF Tx of limited disease
Topical steroids
Topical mustard nitrogen
Radiotherarpy
MF Tx of widespread skin disease
Phototherapy ultraviolet A/B + psoralen
Bv
SS pts were excluded from ALCANZA trial of Bv in MF
MF immunophenotype
Cd3+, CD4+, CD8-, CD30 +/-,
aberrant loss of 1 of:
CD2, C5, CD7
TX of advanced MF/SS with CD30+
BV if CD30+
Mogamulizumab (anti- CCR4) if CD30-
Agents active in MF/SS
Romidepsin
Lenalidomide
Mogamulizumab (CCR4)
Alemtuzumab (CD52)
Bv
Consolidation Tx for SS
Auto or Allo trasplant
Cutaneous ALCL Tx
if localized- RT
Breast implant–associated ALCL
CD30+
ALK-
Tx is surgical removal of implants
if more nodal disease- Tx like RT or Bv-CHP
T-LGL immunophenotype
CD3 and CD8 positive
CD57/CD16 positive
CD56 negative
3+57=60
8+16=24
NK-LGL immunophenotype
CD2+, CD8+,CD16+. CD56+
sCD3− , CD4-, CD57-
LGLL Tx
MTX/CY/CsA
+/- prednisone
2nd line- alemtuzumab
Consider splenectomy
LGLL driver mutation
STAT3